GI-targeted oral JAK inhibitor shows promise in Phase I Study: TD-1473
Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor TD-1473 showed a reduction in plasma exposure compared to?currently-appro…
